ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Cross-cohort validation and cutpoint estimation of the Janssen plasma p-tau217+ assay in predominantly cognitively normal community studies.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217-based assessment of CSF amyloid positivity in secondary-care patients with MCI.Frontiers in aging neuroscience · 2026Article
Corrections and comments
- Update of
Authors and funding
15 authors.
Funding
Abstract
introductionCross-cohort validation studies for plasma phosphorylated tau (p-tau) 217 are limited. We evaluated the Janssen plasma p-tau217+ assay and proposed a cutpoint value in three independent community-based cohorts.
methodsWe included n = 441 participants (age = 70.3 ± 7.3) from three independent community-based cohorts with amyloid-beta-positron emission tomography (Aβ-PET), tau-PET, clinical, and cognitive information.
resultsThe cohorts had low pre-test probability (%Aβ positivity = 14.9-24.7) and were predominantly cognitively normal (> 73%). Plasma p-tau217+ had high accuracy for abnormal Aβ PET (areas under the curve [AUCs] = 81-86%), good correlation with Aβ-PET burden (0.336-0.397) that was highest in the cohort with the most Aβ-PET-positive participants, and the biomarker concentrations were highest in the joint Aβ-PET and tau-PET positive group. Negative predictive value (NPV) was high across cohorts (≤93%) but positive predictive value (PPV) was consistently poor (< 57%). Sensitivity and specificity averaged 75% and 84%, respectively. A combined cohort cutpoint of 0.05pg/ml gave AUC = 84.5%, NPV = 94%, PPV = 50%, sensitivity = 75%, and specificity = 84%. DISCUSSION: Plasma p-tau217+ can rule out Aβ pathophysiology due to Alzheimer's disease at the population level. Cohort-level %Aβ-PET positivity influences accuracies. HIGHLIGHTS: Plasma phosphorylated tau (p-tau) 217 assays have demonstrated potential to identify older adults with brain amyloid pathology due to Alzheimer's disease. Community-based studies are crucial for accessing the clinical validity of fluid biomarkers and their real-world applicability. We evaluated the Janssen plasma p-tau217+ assay in three community-based cohorts. Janssen plasma p-tau217+ identified amyloid-beta abnormalities across three diverse cohorts of community-dwelling older adults. High NPV indicates p-tau217+ as a good tool for initial screening to enrich for high-risk individuals particularly for cohort studies and clinical trial participation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.